Challenges of Portfolio Management in Pharmaceutical Development

Charles Persinger ()
Additional contact information
Charles Persinger: Eli Lilly and Company

Chapter Chapter 5 in Optimization of Pharmaceutical R&D Programs and Portfolios, 2015, pp 71-80 from Springer

Abstract: Abstract Pharmaceutical companies have leveraged traditional portfolio management approaches for over 20 years. This has brought benefits in prioritization of projects and resources and the development of portfolio strategies and goals. However, the nature of drug development creates challenges to a pure implementation of these portfolio management approaches. This paper highlights these challenges and offers approaches to overcome the challenges.

Keywords: Portfolio management; Prioritization; Resource constraints; Portfolio decisions; Project decisions (search for similar items in EconPapers)
Date: 2015
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-319-09075-7_5

Ordering information: This item can be ordered from
http://www.springer.com/9783319090757

DOI: 10.1007/978-3-319-09075-7_5

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().